heterocyclyl are independently substituted with 1 or 2 substituents independently selected from the group consisting of halogen and hydroxy;

R^4 and R^5 are independently hydrogen, halogen, an unsubstituted C_{1-4} alkyl, a deuterated C_{1-4} alkyl or an unsubstituted C_{2-4} alkenyl;

R^6 is hydrogen, an unsubstituted C_{1-4} alkyl, a deuterated C_{1-4} alkyl or an unsubstituted C_{3-4} alkenyl; and

provided that at least one of R^4, R^5 and R^6 is not hydrogen;

X^1 is CR^A or N;

R^{7a}, R^{7b}, R^{7c} and R^{7d} are independently hydrogen, halogen, an unsubstituted C_{1-4} haloalkyl, cyano or an unsubstituted C_{1-4} alkoxy;

R^8 is–$CH_2OC(=O)$–(an unsubstituted C_{1-4} alkyl), –$CH_2OC(=O)$–O(an unsubstituted C_{1-4} alkyl), –CH_2–(α-amino acid) or –CH_2-phosphate; and

R^A is hydrogen, halogen, an unsubstituted C_{1-4} haloalkyl or cyano.

[0004b] In another aspect, there is provided a compound having the structure



, or a pharmaceutically acceptable salt thereof.

[0004c] In another aspect, there is provided a compound having the structure



, or a pharmaceutically acceptable salt thereof.

[0004d] In another aspect, there is provided a compound having the structure



.

[0004e] In another aspect, there is provided a compound having the structure



thereof.

[0004f] In another aspect, there is provided a compound having the structure



, or a pharmaceutically acceptable salt thereof.

[0004g] In another aspect, there is provided a compound having the structure



, or a pharmaceutically acceptable salt thereof.

[0004h] In another aspect, there is provided a compound having the structure



, or a pharmaceutically acceptable salt thereof.

WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:



(I)

wherein:

R^1 is an unsubstituted or a substituted C_2 alkenyl or an unsubstituted or a substituted C_2 alkynyl, wherein when the C_2 alkenyl and the C_2 alkynyl are substituted, the C_2 alkenyl and the C_2 alkynyl are independently substituted with one or more substituents independently selected from the group consisting of halogen, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{1-4} haloalkyl, an unsubstituted C_{1-4} hydroxyalkyl, an unsubstituted monocyclic C_{3-6} cycloalkyl and a hydroxy-substituted monocyclic C_{3-6} cycloalkyl;

R^2 and R^3 are independently selected from the group consisting of hydrogen, an unsubstituted or a substituted C_{1-4} alkyl, an unsubstituted C_{1-4} haloalkyl, an unsubstituted or a substituted monocyclic C_{3-6} cycloalkyl, an unsubstituted or a substituted monocyclic 3-6 membered heterocyclyl, an unsubstituted C_{1-4} hydroxyalkyl and an unsubstituted C_{1-5} alkoxyalkyl, wherein when the monocyclic C_{3-6} cycloalkyl and the monocyclic 3-6 heterocyclyl are substituted, the monocyclic C_{3-6} cycloalkyl and the monocyclic 3-6 heterocyclyl are independently substituted with one or more substituents selected from the group consisting of halogen or hydroxy, and wherein when the C_{1-4} alkyl is substituted, the C_{1-4} alkyl is substituted with one or more substituents independently selected from the group consisting of a phosphate, an O-linked α-amino acid and an O-carboxy, and provided that at least one of R^2 and R^3 is not hydrogen; or

R^2 and R^3 are taken together along with the carbon to which R^2 and R^3 are attached to form an unsubstituted or a substituted monocyclic C_{3-6} cycloalkyl or an unsubstituted or a substituted monocyclic 3-6 membered heterocyclyl, wherein when the C_{3-6} cycloalkyl and 3-6 membered heterocyclyl are substituted, the C_{3-6} cycloalkyl and the 3-6 membered heterocyclyl are

independently substituted with 1 or 2 substituents independently selected from the group consisting of halogen and hydroxy;

R^4 and R^5 are independently hydrogen, halogen, an unsubstituted C_{1-4} alkyl, a deuterated C_{1-4} alkyl or an unsubstituted C_{2-4} alkenyl;

R^6 is hydrogen, an unsubstituted C_{1-4} alkyl, a deuterated C_{1-4} alkyl or an unsubstituted C_{3-4} alkenyl; and

provided that at least one of R^4, R^5 and R^6 is not hydrogen;

X^1 is CR^A or N;

R^{7a}, R^{7b}, R^{7c} and R^{7d} are independently hydrogen, halogen, an unsubstituted C_{1-4} haloalkyl, cyano or an unsubstituted C_{1-4} alkoxy;

R^8 is–$CH_2OC(=O)$–(an unsubstituted C_{1-4} alkyl), –$CH_2OC(=O)$–O(an unsubstituted C_{1-4} alkyl), –CH_2–(α-amino acid) or –CH_2-phosphate; and

R^A is hydrogen, halogen, an unsubstituted C_{1-4} haloalkyl or cyano.

2. The compound of Claim 1, wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{1-4} haloalkyl, an unsubstituted or a substituted monocyclic C_{3-6} cycloalkyl, an unsubstituted or a substituted monocyclic 3-6 membered heterocyclyl, an unsubstituted C_{1-4} hydroxyalkyl and an unsubstituted C_{1-5} alkoxyalkyl, wherein when the monocyclic C_{3-6} cycloalkyl and the monocyclic 3-6 heterocyclyl are substituted, the monocyclic C_{3-6} cycloalkyl and the monocyclic 3-6 heterocyclyl are independently substituted with one or more substituents selected from the group consisting of halogen or hydroxy.

3. The compound of Claim 1, wherein R^2 and R^3 are taken together along with the carbon to which R^2 and R^3 are attached to form an unsubstituted or a substituted monocyclic C_{3-6} cycloalkyl or an unsubstituted or a substituted monocyclic 3-6 membered heterocyclyl, wherein when the C_{3-6} cycloalkyl and 3-6 membered heterocyclyl are substituted, the C_{3-6} cycloalkyl and the 3-6 membered heterocyclyl are independently substituted with 1 or 2 substituents selected from the group consisting of halogen and hydroxy.

4. The compound of Claim 3, wherein the monocyclic 3-6 membered heterocyclyl is selected from the group consisting of an unsubstituted or substituted oxetane, an unsubstituted or substituted thietane, an unsubstituted or substituted , an unsubstituted or substituted

 , an unsubstituted or substituted  , an unsubstituted or substituted  , an unsubstituted or substituted  and an unsubstituted or substituted  .

5. The compound of any one of Claims 1-4, wherein R^4 is an unsubstituted C_{1-4} alkyl; R^5 is an unsubstituted C_{1-4} alkyl; and R^6 is an unsubstituted C_{1-4} alkyl.

6. The compound of any one of Claims 1-5, wherein X^1 is CR^A.

7. The compound of Claim 6, wherein R^A is halogen.

8. The compound of any one of Claims 1-7, wherein R^{7a} is hydrogen; and R^{7d} is hydrogen.

9. The compound of any one of Claims 1-8, wherein R^{7b} is halogen, an unsubstituted C_{1-4} haloalkyl, cyano or an unsubstituted C_{1-4} alkoxy.

10. The compound of any one of Claims 1-9, wherein R^{7c} is hydrogen.

11. The compound of any one of Claims 1-10, wherein R^1 is an unsubstituted C_2 alkenyl.

12. The compound of any one of Claims 1-10, wherein R^1 is an unsubstituted C_2 alkynyl.

13. The compound of any one of Claims 1-12, wherein R^8 is $–CH_2OC(=O)–$(an unsubstituted C_{1-4} alkyl), $–CH_2OC(=O)–O$(an unsubstituted C_{1-4} alkyl) or $–CH_2–$(α-amino acid).

14. The compound of any one of Claims 1-12, wherein R^8 is $–CH_2$-phosphate.

15. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-14, or a pharmaceutically acceptable salt thereof, and excipient.

16. Use of the compound of any one of Claims 1-14, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of hepatitis B.

17. Use of the compound of any one of Claims 1-14, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of hepatitis D.

18. The use of any one of Claims 16-17, wherein the use further comprises the use of one or more additional agents selected from the group consisting of an interferon, a nucleoside

analog, a nucleotide analog, a sequence specific oligonucleotide, a nucleic acid polymer, an entry inhibitor and a small molecule immunomodulator.

19. The use of Claim 18, wherein the one or more additional agents are selected from the group consisting of recombinant interferon alpha 2b, IFN-α, PEG-IFN-α-2a, lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide and tenofovir disoproxil.

20. A compound of any one of Claims 1-14, or a pharmaceutically acceptable salt thereof, for use in treating hepatitis B.

21. A compound of any one of Claims 1-14, or a pharmaceutically acceptable salt thereof, for use in treating hepatitis D.

22. The compound for use of any one of Claims 20-21, wherein the compound is used in combination with one or more additional agents selected from the group consisting of an interferon, a nucleoside analog, a nucleotide analog, a sequence specific oligonucleotide, a nucleic acid polymer, an entry inhibitor and a small molecule immunomodulator.

23. The compound for use of Claim 22, wherein the one or more additional agents are selected from the group consisting of recombinant interferon alpha 2b, IFN-α, PEG-IFN-α-2a, lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide and tenofovir disoproxil.

24. A compound having the structure



, or a pharmaceutically acceptable salt thereof.

25. A compound having the structure , or a pharmaceutically acceptable salt thereof.

26. A compound having the structure .

27. A compound having the structure .

28. A compound having the structure , or a pharmaceutically acceptable salt thereof.

29. A compound having the structure , or a pharmaceutically acceptable salt thereof.

30. A compound having the structure



, or a pharmaceutically acceptable salt thereof.

31. The compound of Claim 1, wherein:

R^1 is an unsubstituted or a substituted C_2 alkynyl, wherein when the C_2 alkynyl is substituted, the C_2 alkynyl is substituted with one or more substituents independently selected from the group consisting of halogen, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{1-4} haloalkyl, an unsubstituted C_{1-4} hydroxyalkyl, an unsubstituted monocyclic C_{3-6} cycloalkyl and a hydroxy-substituted monocyclic C_{3-6} cycloalkyl;

R^2 and R^3 are taken together along with the carbon to which R^2 and R^3 are attached to form an unsubstituted or a substituted monocyclic 3-6 membered heterocyclyl, wherein when 3-6 membered heterocyclyl are substituted, the 3-6 membered heterocyclyl is substituted with 1 or 2 substituents independently selected from the group consisting of halogen and hydroxy;

R^4 and R^5 are each an unsubstituted C_{1-4} alkyl;

R^6 is an unsubstituted C_{1-4} alkyl;

X^1 is CR^A;

R^{7a}, R^{7c} and R^{7d} are each hydrogen;

R^{7b} is halogen, an unsubstituted C_{1-4} haloalkyl, cyano or an unsubstituted C_{1-4} alkoxy; and

R^A is halogen.

32. The compound of Claim 31, wherein:

R^1 is an unsubstituted C_2 alkynyl;

R^2 and R^3 are taken together along with the carbon to which R^2 and R^3 are attached to form an unsubstituted or a substituted monocyclic 3-4 membered heterocyclyl, wherein when 3-4 membered heterocyclyl are substituted, the 3-4 membered heterocyclyl is substituted with 1 or 2 substituents independently selected from the group consisting of halogen and hydroxy;

R^4 and R^5 are each an unsubstituted C_{1-4} alkyl;

R^6 is an unsubstituted C_{1-4} alkyl;

X^1 is CR^A;

R^{7a}, R^{7c} and R^{7d} are each hydrogen;

R^{7b} is an unsubstituted C_{1-4} haloalkyl or cyano; and

R^A is halogen.

33. The compound of Claim 31 or 32, wherein R^4 is methyl; R^5 is methyl; and R^6 is methyl.

34. The compound of any one of Claims 31-33, wherein R^A is fluoro.

35. The compound of any one of Claims 31-34, wherein R^{7b} is cyano.

36. The compound of any one of Claims 31-34, wherein R^{7b} is $–CF_3$.

37. The compound of any one of Claims 31-36, wherein R^2 and R^3 are taken together along with the carbon to which R^2 and R^3 are attached to form an unsubstituted oxetane.

38. The compound of Claim 37, wherein R^8 is $–CH_2$-phosphate.